Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4 - PubMed (original) (raw)
Comparative Study
Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4
C A Fargeas et al. J Exp Med. 1995.
Abstract
The CD80 (B7-1) molecule is a 45-60-kD member of the immunoglobulin superfamily that is expressed on a variety of cell types of haematopoietic origin. CD80 can provide a critical costimulatory signal to T cells by interacting with the T cell surface molecule CD28. CD80 also binds to the CD28-related molecule CTLA4, which is expressed on activated T cells, Recently, additional ligands of CD28 and CTLA4 have been described in mice and humans. One of them, CD86 (B-70 or B7-2) was characterized at the molecular level. Although similar in predicted structure to CD80, it is distantly related in amino acid sequence. In this study, human CD80 mutants were generated and tested for their ability to maintain the interaction with CD28 leading to adhesion and enhanced IL-2 production. Two hydrophobic residues in the V-like domain of CD80 were identified as critical for binding to CD28 and are also important for the interaction with CTLA4. These residues are adjacent to the epitope of the BB1 antibody, which inhibits CD28-CD80 interactions. One of these residues, Y87, is conserved in all CD80 and CD86 cloned from various species. These results being to unravel the structural requirements for binding to CD28 and CTLA4.
Similar articles
- Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
Guo Y, Wu Y, Zhao M, Kong XP, Liu Y. Guo Y, et al. J Exp Med. 1995 Apr 1;181(4):1345-55. doi: 10.1084/jem.181.4.1345. J Exp Med. 1995. PMID: 7535334 Free PMC article. - Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28.
Peach RJ, Bajorath J, Naemura J, Leytze G, Greene J, Aruffo A, Linsley PS. Peach RJ, et al. J Biol Chem. 1995 Sep 8;270(36):21181-7. doi: 10.1074/jbc.270.36.21181. J Biol Chem. 1995. PMID: 7545666 - Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.
Truneh A, Reddy M, Ryan P, Lyn SD, Eichman C, Couez D, Hurle MR, Sekaly RP, Olive D, Sweet R. Truneh A, et al. Mol Immunol. 1996 Feb;33(3):321-34. doi: 10.1016/0161-5890(95)00077-1. Mol Immunol. 1996. PMID: 8649453 - Regulation of T and B cell responses by modulating interactions between CD28/CTLA4 and their ligands, CD80 and CD86.
Lane P. Lane P. Ann N Y Acad Sci. 1997 Apr 5;815:392-400. doi: 10.1111/j.1749-6632.1997.tb52090.x. Ann N Y Acad Sci. 1997. PMID: 9186685 Review. - CD28/CTLA-4 and CD80/CD86 families: signaling and function.
Slavik JM, Hutchcroft JE, Bierer BE. Slavik JM, et al. Immunol Res. 1999;19(1):1-24. doi: 10.1007/BF02786473. Immunol Res. 1999. PMID: 10374692 Review.
Cited by
- The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.
Maurer MF, Lewis KE, Kuijper JL, Ardourel D, Gudgeon CJ, Chandrasekaran S, Mudri SL, Kleist KN, Navas C, Wolfson MF, Rixon MW, Swanson R, Dillon SR, Levin SD, Kimbung YR, Akutsu M, Logan DT, Walse B, Swiderek KM, Peng SL. Maurer MF, et al. Nat Commun. 2022 Apr 4;13(1):1790. doi: 10.1038/s41467-022-29286-5. Nat Commun. 2022. PMID: 35379805 Free PMC article. - CTLA-4-B7 interaction is sufficient to costimulate T cell clonal expansion.
Wu Y, Guo Y, Huang A, Zheng P, Liu Y. Wu Y, et al. J Exp Med. 1997 Apr 7;185(7):1327-35. doi: 10.1084/jem.185.7.1327. J Exp Med. 1997. PMID: 9104819 Free PMC article. - Costimulatory receptors in the channel catfish: CD28 family members and their ligands.
Quiniou SMA, Bengtén E, Boudinot P. Quiniou SMA, et al. Immunogenetics. 2024 Feb;76(1):51-67. doi: 10.1007/s00251-023-01327-3. Epub 2024 Jan 10. Immunogenetics. 2024. PMID: 38197898 - Effects of superantigen and lipopolysaccharide on induction of CD80 through apoptosis of human monocytes.
Takahashi M, Takahashi M, Shinohara F, Takada H, Rikiishi H. Takahashi M, et al. Infect Immun. 2001 Jun;69(6):3652-7. doi: 10.1128/IAI.69.6.3652-3657.2001. Infect Immun. 2001. PMID: 11349026 Free PMC article. - CD28: a signalling perspective.
Ward SG. Ward SG. Biochem J. 1996 Sep 1;318 ( Pt 2)(Pt 2):361-77. doi: 10.1042/bj3180361. Biochem J. 1996. PMID: 8809021 Free PMC article. Review.
References
- Nature. 1990 Nov 29;348(6300):419-26 - PubMed
- Immunology. 1990 Apr;69(4):531-5 - PubMed
- J Immunol. 1991 Aug 1;147(3):1037-44 - PubMed
- J Exp Med. 1991 Sep 1;174(3):561-9 - PubMed
- J Exp Med. 1991 Sep 1;174(3):625-31 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous